Fosun Pharma gets drug application accepted for cancer treatment
Shanghai Fosun Pharmaceutical announced that regulators accepted the drug registration application for Nedaplatin for injection, developed by subsidiary Kisma (Wuhan) Pharmaceutical.
The self-developed chemical drug targets head and neck cancer, small cell lung cancer, and ovarian cancer. Fosun has invested approximately RMB 5.66 million in research and development for the drug as of July 2025.
According to IQVIA data, Nedaplatin for injection generated sales of approximately RMB 353 million in mainland China during 2024.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
News Alerts
Get instant email alerts when Shanghai Fosun Pharmaceutical Group publishes news
Free account required • Unsubscribe anytime